Journal of Clinical Medicine, Volume 12, Issue 5
2023 March-1 - 377 articles
Cover Story: Mutational activation of the epidermal growth factor receptor (EGFR) is a frequent event in non-small cell lung cancer (NSCLC) that contributes to malignant growth. These bona fide driver mutations are important therapeutic targets. While on-target mutations that prevent EGFR inhibitor (EGFRi) binding are a frequent complication, mutational activation of bypass pathways can occur as well. Therapeutic intervention is complicated by an additional duality of resistance mechanisms that are not only mutational but can also include a significant amount of nonmutational activation. Thus, precision medicine takes center stage in defining therapeutic intervention and future drug development. To overcome resistance, we must arrive at therapeutics to encompass both genetic and nongenetic mechanisms. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.